I recently helped out at the E-Reps 2017 conference by manning the reception and timing the speakers. It was such a great experience!
The E-Reps Forum is an annual one-day conference intended to bring together people with an interest in environmental best practice in the oil and gas industry. I already knew about those people who volunteer as environmental reps in their companies, but being at the Forum gave me a glimpse at the complexity and challenges of their endeavours.
Read more about my day on LinkedIn.
One of my articles for Research Features came out in issue 106. It's about fluorescent proteins as intracellular markers.
Check it out on their website.
I finally took the time for a wee excursion down the river Don to have a look at the new hydro energy station. It all started as a community project and successfully went through a few funding rounds, including selling bonds to private investors. Find out more on their website.
I have written an article assessing the pros and cons of fluorescent quantum dots in FACS.
Read it on BiteSize Bio.
Dr Sue Lederer (space scientist) and Rick Hieb (former astronaut) came all the way from the US to Scotland to spend a week packed full of activities of public engagement and school visits. On 30th Jan 2017 I went to their presentation at Robert Gordon's College in Aberdeen to listen to them talk about working in space and bust some of the flaws in the movie ‘Gravity’.
Is it possible to work with autistic people in a regular workplace? - Project ‘Opportunity’ has proven that a controlled and thoughtful approach to integration can provide a company with valuable staff and autistic people with a job, purpose and satisfaction.
It may be hard to believe but a pharmacy talk can actually be entertaining. Prof Derek Stewart made sure of that whilst conveying some important key insights of his group’s research.
Daclizumab, marketed as Zinbryta, was approved for the treatment of relapsing-remitting multiple sclerosis (MS) in the USA and Europe in summer 2016. Daclizumab has shown superior efficacy when compared to placebo and a standard treatment (AVONEX®, interferon beta-1a) and is believed to be on a par with other novel treatments. It is a once-monthly subcutaneous injection which the patient can administer themselves. This is quite convenient to be honest and if you aren’t into injecting yourself, you can go to your doctor as far as I have heard.
After I tweeted about my recent post Immunicum - Scalable Personalised Cancer Immunotherapy, another Twitter user made me aware of iCancer. Why? – Because the clinical trial financed through the iCancer fundraising campaign used the Ad5PTDf35-adenovirus vector which Immunicum includes as one of their treatment platforms under development.
I thought I kick off the year with an article about Immunicum, a Swedish company I stumbled across a week or so ago.
As an immunologist by training I have a soft spot for companies looking to exploit the versatility and strength of our own immune system. Immunicum does just that. In their own words, they aim to create “the blue print for the world's first personalised, off-the-shelf affordable cancer treatment” which improves both survival and quality of life.